In a preclinical mouse model, targeting of chemokine ligand 12 (CXCL12) improved antitumor immunity and caused tumor reduction via T cell activity and upregulation of PD-L1 and CTLA-4, highlighting the role of CXCL12 in immune response evasion [219]. This evidence concerns the gene CXCL12 and neoplasm.